This suggests that amylin may either increase in parallel with body weight as a compensatory mechanism aimed at reducing adiposity or that obesity-induced resistance to amylin’s effects leads to its upregulation. The gene discussed is IAPP; the disease is obesity due to melanocortin 4 receptor deficiency.